Michael A. Postow, MD

Panelists discuss real-world evidence comparing immunotherapy combinations for metastatic melanoma, highlighting retrospective analyses showing similar efficacy between nivolumab plus relatlimab and nivolumab plus ipilimumab, while emphasizing the relatlimab-based regimen’s lower toxicity and the need for individualized treatment decisions in patients who fall outside typical clinical trial populations.

Panelists discuss the prioritization of immunotherapy over targeted therapy for BRAF-mutant metastatic melanoma, highlighting updated RELATIVITY-047 data supporting nivolumab plus relatlimab for its durable efficacy and favorable toxicity profile, and emphasizing the importance of individualized treatment selection based on evolving evidence, patient goals, and comparative analyses of combination regimens.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.

Panelists discuss evolving frontline treatment strategies for metastatic melanoma, emphasizing recent clinical updates—particularly 4-year data from the RELATIVITY-047 trial—and exploring how these findings, including the benefits of nivolumab plus relatlimab, inform real-world decision-making for complex cases like BRAF-mutant disease with high tumor burden.

In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.

As part of our 2015 ASCO Annual Meeting coverage, we discussed immunotherapy combinations in advanced melanoma patients with Michael A. Postow, MD.

This review will summarize the preclinical and clinical development of CTLA-4–blocking antibodies, discuss recent insights into the biology of CTLA-4 blockade, review the use of these antibodies in combination with established and novel therapeutic modalities, and comment on ongoing questions regarding their administration.